GlassScriptPhysician profile
Michael G Kizy
NPI 1750364550
$4,780.63
in general payments reported to CMS, 2019-2025
27 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $316 · 2021: $445 · 2022: $854 · 2023: $827 · 2024: $803 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,754.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,012.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $570.59 | 2019-2024 | Evenity, Prolia, Repatha |
| Pfizer INC. | $565.73 | 2019-2025 | |
| Abbvie INC. | $517.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $393.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $307.86 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $245.94 | 2019-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $233.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $165.58 | 2019-2023 | |
| Exact Sciences Corporation | $140.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $118.70 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $72.09 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.72 | 2020-2022 | |
| Dexcom, INC. | $60.43 | 2022-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $50.77 | 2022-2025 | Capvaxive, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $31.67 | 2024-2025 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $31.65 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $31.34 | 2024 | Voquezna |
| Biogen, INC. | $26.25 | 2025 | Skyclarys |
| Kowa Pharmaceuticals America, INC. | $24.94 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $17.65 | 2021 | |
| Horizon Therapeutics Plc | $17.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.96 | 2022 | |
| Seqirus USA INC | $16.45 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Hikma Pharmaceuticals USA | $15.96 | 2023 | Mitigare, Ryaltris |
| Biohaven Pharmaceuticals, INC. | $14.99 | 2021 | |
| Sanofi Pasteur INC. | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kizy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.